Distribution of the Bowman Birk protease inhibitor in mice following oral administration

Paul C. Billings, William H.St Clair, Patricia A. Maki, Ann R. Kennedy

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


In this study, the distribution of the soybean-derived Bowman Birk inhibitor (BBI) in mice was examined. Mice received [125I]BBI by oral gavage and three hours later, the mice were sacrificed, the organs of interest were carefully removed and the distribution of the inhibitor was determined. The bulk of labeled BBI was present in the luminal contents of the small and large bowel, urine and feces. Significant amounts of label were also observed in the serum, esophagus, stomach and intestine, kidney, liver and lung. Analysis of tissue homogenates by gel filtration chromatography revealed that the radioactivity eluted from the column at the same position as the BBI standard indicating that the iodinated BBI was still intact. The chromatographically purified BBI was able to inhibit chymotrypsin indicating that functional protease inhibitory activity was present. These results indicate that the BBI becomes widely distributed in mice 3 h after oral administration and that intact protease inhibitor is present in internal organs.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalCancer Letters
Issue number3
StatePublished - Mar 15 1992

Bibliographical note

Funding Information:
This work was supported by NIH grants CA45734 and CA46496.


  • anticarcinogenesis
  • distribution
  • protease inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Distribution of the Bowman Birk protease inhibitor in mice following oral administration'. Together they form a unique fingerprint.

Cite this